Raza A, Maheshwari Y, Yasin Z, Mandava N, Mayers G, Preisler H D
Department of Hematologic Oncology, Roswell Park Memorial Institute, Buffalo, NY 14263.
Leuk Res. 1987;11(12):1079-87. doi: 10.1016/0145-2126(87)90160-3.
Ten patients with acute nonlymphocytic leukemia (ANLL) received bromodeoxyuridine (BrdU) at 100 mg/M2 intravenously over 1 h. BrdU is incorporated into the DNA by S-phase cells and was detected by using a monoclonal anti-BrdU antibody in the bone marrow aspirate (BM) and biopsy specimens obtained at the end of the infusion. Additionally, BM was incubated in vitro with tritiated thymidine (3HTdr) and processed by our previously described double-label method. This allowed us to measure the duration of S-phase (Ts) and total cell cycle time (Tc) of myeloblasts. Data revealed a higher number of S-phase cells from biopsies (21%) than BM (5%). The Ts ranged from 9 to 35 h and Tc ranged between 36 and 152 h in different patients. Using this method, data are available within 48 h and if shown to be clinically relevant, may be useful for prospective planning of therapy in individual patients.
10例急性非淋巴细胞白血病（ANLL）患者接受了100mg/M²的溴脱氧尿苷（BrdU）静脉注射，持续1小时。BrdU由S期细胞掺入DNA，并通过在输注结束时获取的骨髓穿刺液（BM）和活检标本中使用单克隆抗BrdU抗体进行检测。此外，将BM与氚标记的胸腺嘧啶核苷（3HTdr）进行体外孵育，并通过我们先前描述的双标记方法进行处理。这使我们能够测量成髓细胞的S期持续时间（Ts）和总细胞周期时间（Tc）。数据显示，活检标本中的S期细胞数量（21%）高于骨髓穿刺液中的（5%）。不同患者的Ts范围为9至35小时，Tc范围为36至152小时。使用这种方法，48小时内即可获得数据，如果证明具有临床相关性，可能有助于对个体患者进行前瞻性治疗规划。
